Long-acting HIV shot studied in patients with severe kidney problems

NCT ID NCT05601128

Completed Disease control Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study looks at whether CABENUVA, a long-acting injectable HIV medication, is safe and effective for people with HIV who also have severe kidney impairment, including those on dialysis. Participants receive the drug as monthly or every-2-month injections. The goal is to see how the drug behaves in the body and whether it keeps the virus suppressed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a long-acting injectable combination of cabotegravir and rilpivirine
What this could lead to: If successful, this could show that people with severe kidney disease can safely use long-acting injectable HIV treatment instead of daily pills.
What could go wrong: This is a small study with only 12 participants, so results may not apply to everyone. Kidney disease can affect how drugs are processed, and side effects may differ.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV -1 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV -1 INFECTION HIV I INFECTION HIV INFECTIONS

Contacts and locations

Show contact details

Locations

Allegheny Health Network

Pittsburgh, Pennsylvania, 15212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.